Risk Statement: NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.
Another unusual aspect of the Roundup cases is that Monsanto has not issued a recall and continues to sell the product. Presumably, people will continue to get sick from use of the product and cases will continue to be filed against Monsanto. As of now, however, these future cases are not eligible to participate in the current settlement, although it is likely that Monsanto at some point will open the settlement for “Round 2” claimants.
Since the relationship between Elmiron and retinal damage has only recently been discovered, many clients will have been misdiagnosed with eye disease thought to have been caused by other factors when their condition was actually related to the drug.
Traces of glyphosate, a weed-killing chemical, has been found in various samples of hummus and chickpeas, according to a new report out today from the Environmental Working Group.
FDA advises consumers not to use hand sanitizer products by multiple manufacturers Due to the Potential Presence of Undeclared Methanol (Wood Alcohol)
If you do use e-cigarette products and you experience symptoms like those reported in this outbreak, seek medical care promptly. CDC and the FDA will continue to alert the public throughout this investigation.
Torrent Pharmaceuticals Limited is voluntarily recalling 2 lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of a probable human carcinogen.
NYC hospitals continues their poor performance on Leapfrog's hospital safety grades list, with most earning Cs or Ds. Healthcare providers in all five boroughs once again performed poorly in Leapfrog's* Fall 2018 ratings for hospital safety. More than 50% of 44 New York City facilities graded earned a C grade and only three facilities managed a B [...]
FDA is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs.
Generic drugs may not provide an adequate level of protection to the patient.